Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Vertex Pharmaceuticals (NQ: VRTX)
176.23 USD  -1.49 (-0.84%)
Official Closing Price  /  Updated: 4:48 PM EDT, Oct 18, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 1,122,500
Open 180.25
Bid (Size) 176.20 (5)
Ask (Size) 182.00 (2)
Prev. Close 177.72
Today's Range 175.38 - 180.25
52wk Range 151.80 - 195.81
Shares Outstanding 254,830,232
Dividend Yield N/A
Performance
YTD
+7.40%
+7.40%
1 Month
+0.05%
+0.05%
3 Month
+1.24%
+1.24%
6 Month
+4.58%
+4.58%
1 Year
+0.31%
+0.31%
Top News
More News
Vertex Announces Reimbursement of Cystic Fibrosis Medicines SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Patients Ages 12 and Older, and ORKAMBI® (lumacaftor/ivacaftor) in Children Ages
Vertex announced reimbursement of SYMDEKO for eligible patients ages 12 and older, and ORKAMBI for children ages 2 to 5 in Australia. Read More
from Business Wire News Releases
Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Eligible Infants with Cystic Fibrosis as Early as 6 Months of Age
Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO®... Read More
from Business Wire News Releases
More News
Read More
Vertex Appoints Carmen Bozic, M.D., as New Chief Medical Officer and Nia Tatsis, Ph.D., as New Chief Regulatory Officer
from Business Wire News Releases
Vertex and Ribometrix Establish Strategic Collaboration to Discover and Develop RNA-Targeted Small Molecule Therapeutics
from Business Wire News Releases
2 High-Growth Stocks to Buy Right Now
category Market News , VRTX , BMRN
from Motley Fool
Hedge Funds Have Never Been This Bullish On Infosys Limited
category Technology , Stocks / Equities
from Blogs - TalkMarkets
3 Reasons Vertex Pharmaceuticals Is Poised for a Big Year
category VRTX , Market News , CRSP
from Motley Fool
Noteworthy ETF Outflows: IBB, CELG, VRTX, ILMN
category ETFs
from ETF Channel
Forget Vertex Pharmaceuticals; CRISPR Therapeutics Is a Better Biotech Growth Stock
category EDIT , NTLA , NVS , and 5 more.
from Motley Fool
VRTX November 8th Options Begin Trading
category Stocks
from Market News Video
A Biotech Set to Dominate the Next 20 Years
category AKCA , RHHBY , GSK , and 8 more.
from Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
X